People default image

Pablo Hernandez Romero

Associate
Los Angeles
About
Pablo Hernandez Romero focuses on representing startup and emerging growth companies across market industries throughout their corporate lifecycle including from initial planning, formation and structuring, SAFE, convertible debt, and venture capital financings, cross-border transactions, general corporate governance, international reorganizations, securities laws compliance matters, intellectual property protections, employment and equity matters and mergers and acquisitions.
Areas of FocusEmerging Growth and Venture CapitalCorporate Venture CapitalMergers and AcquisitionsTechnologyMedia, Sport and EntertainmentConsumer Goods
Bar admissionsCaliforniaMassachusetts

EXPERIENCE

Start-up and Venture Capital
  • Numerous venture capital firms in early and stage seed financings through late-stage growth equity financings including EQT Ventures, a16z, Upfront Ventures, Elysian Park Ventures, Base1, Susa Ventures, Menlo Ventures*
  • Representing corporate venture capitalists, including Microsoft Ventures, GE Healthcare, Murata, Hanwha and FF2032
Mergers and Acquisitions
  • Buy-Side Representation: 
    • FalconX Holdings Limited in its acquisition of Arbelos Markets, Inc.*
    • BitSight Technologies, Inc. in its acquisitions of:
      • Cybersixgill Ltd.*
      • VisibleRisk, Inc.*
      • Northern Lights Group, Inc. (d/b/a Third Party Trust)*
    • Intellia Therapeutics, Inc. (NASDAQ: NTLA) in its acquisition of Rewrite Therapeutics, Inc.*
    • RBC Bearings Incorporated (NASDAQ: ROLL) in its acquisition of ABB's Dodge Mechanical Power Transmission division*
    • Synaptics Incorporated (NASDAQ: SYNA) in its acquisition of DSP Group, Inc. (NASDAQ: DSPG)*
  • Sell-Side Representation:
    • SwiftComply, Inc. in its majority sale to M33 Growth*
    • Parsable Inc. in its sale to CAI Software, LLC*
    • Thrive Earlier Detection Corp. in its sale to Exact Sciences Corp. (NASDAQ: EXAS)*
Public Company and Capital Markets Transactions
  • Intellia Therapeutics, Inc. in connection with its:
    • $201 million follow-on offering*
    • $690 million follow-on offering (2022 LMG Life Sciences Impact Deal of the Year)*
    • $300 million bought deal*
    • $400 million "at the market" offering*
  • Centessa Pharmaceuticals plc in connection with its:
    • $100 million follow-on offering*
    • Upsized $379.5 million initial public offering (2021 LMG Life Sciences Impact Deal of the Year)*
    • $125 million "at the market" offering*

*Denotes experience at prior firm.

Education

  • J.D., Northeastern University School of Law, (2020)
    Senior Note Editor, Northeastern University Law Review
    Co-Chair, Student Bar Association 

  • M.Sc., International and European Politics, The University of Edinburgh, (2013) 

  • B.A., Politics, Earlham College, (2012)
    college honors

Prior Experience

Prior to joining DLA Piper, Pablo was a corporate associate at a Boston-based AmLaw20 firm in their Boston and Santa Monica offices. He represented various clients in public company work, mergers and acquisitions transactions, venture capital and other general corporate matters.

Memberships and Affiliations

  • Hispanic National Bar Association
CallvCardLinkedInPrint

Connect

Phone

+1 310 595 3104
(Work, Los Angeles)